Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Leases (2021 - 2025)

Vivos Therapeutics has reported Leases over the past 5 years, most recently at $4.2 million for Q4 2025.

  • Quarterly Leases rose 303.68% to $4.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.2 million through Dec 2025, up 303.68% year-over-year, with the annual reading at $4.2 million for FY2025, 303.68% up from the prior year.
  • Leases was $4.2 million for Q4 2025 at Vivos Therapeutics, up from $3.4 million in the prior quarter.
  • Over five years, Leases peaked at $4.2 million in Q4 2025 and troughed at $516000.0 in Q4 2021.
  • The 5-year median for Leases is $1.5 million (2023), against an average of $1.7 million.
  • Year-over-year, Leases tumbled 31.11% in 2023 and then skyrocketed 303.68% in 2025.
  • A 5-year view of Leases shows it stood at $516000.0 in 2021, then soared by 228.49% to $1.7 million in 2022, then dropped by 18.29% to $1.4 million in 2023, then fell by 25.49% to $1.0 million in 2024, then skyrocketed by 303.68% to $4.2 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Leases are $4.2 million (Q4 2025), $3.4 million (Q3 2025), and $3.2 million (Q2 2025).